Overview

  • Product nameAnti-FGFR1 antibody
    See all FGFR1 primary antibodies
  • Description
    Goat polyclonal to FGFR1
  • SpecificityThis antibody is expected to recognise 5 (out of nine reported) isoforms (as represented by NP_000595; NP_056934; NP_075593; NP_075594; NP_075599)
  • Tested applicationsSuitable for: ELISA, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Cow, Dog, Chimpanzee
  • Immunogen

    Synthetic peptide:

    CLPRHPAQLANGGLKR

    , corresponding to C terminal amino acids 806-821 of Human FGFR1

  • Positive control
    • Human breast lysate

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab31324 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/32000.
WB Use a concentration of 0.3 - 1 µg/ml. Detects a band of approximately 75 kDa (predicted molecular weight: 82 kDa).Can be blocked with FGFR1 peptide (806-821) (ab45685).

Target

  • FunctionReceptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF).
  • Tissue specificityDetected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells.
  • Involvement in diseaseDefects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
    Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
    Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
    Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
    Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
    Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Binding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor.
  • Cellular localizationMembrane. Nucleus. Cytoplasm. Cytoplasmic vesicle
  • Information by UniProt
  • Database links
  • Alternative names
    • Basic fibroblast growth factor receptor 1 antibody
    • bFGF-R-1 antibody
    • BFGFR antibody
    • CD331 antibody
    • CEK antibody
    • FGFBR antibody
    • FGFR 1 antibody
    • FGFR-1 antibody
    • FGFR1 antibody
    • FGFR1/PLAG1 fusion antibody
    • FGFR1_HUMAN antibody
    • fibroblast growth factor receptor 1 antibody
    • FLG antibody
    • FLT-2 antibody
    • FLT2 antibody
    • Fms-like gene antibody
    • Fms-like tyrosine kinase 2 antibody
    • fms-related tyrosine kinase 2 antibody
    • HBGFR antibody
    • heparin-binding growth factor receptor antibody
    • HH2 antibody
    • HRTFDS antibody
    • hydroxyaryl-protein kinase antibody
    • KAL2 antibody
    • N-SAM antibody
    • OGD antibody
    • Proto-oncogene c-Fgr antibody
    see all

Anti-FGFR1 antibody images

  • Anti-FGFR1 antibody (ab31324) at 0.3 µg/ml (incubation time: 1 hour) + Human Breast lysate (35µg protein in RIPA buffer)
    Developed using the ECL technique

    Predicted band size : 82 kDa
    Observed band size : 75 kDa (why is the actual band size different from the predicted?)

References for Anti-FGFR1 antibody (ab31324)

This product has been referenced in:
  • Chase A  et al. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 98:103-6 (2013). WB ; Human . Read more (PubMed: 22875613) »

See 1 Publication for this product

Product Wall

Thank you for your message. I have confirmed with the laboratory that in western blot testing, antibody ab31324 detects only a 74kDa band. I can suggest that the 74kDa isoform is quite abundant, whereas the other isoforms are perhaps much rarer. ...

Read More

Thank you for your enquiry. I can confirm that FGFR1 has several isoforms of different molecular weights. The epitopes for these antibodies will be present on different isoforms of the protein. ab824 is specifically raised against the ectodomai...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"